BLCA prognostic model creation and validation based on immune gene-metabolic gene combination

Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, Chen W. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135:584–90.

Xiang Z, Ye Z, Ma J, Lin Y, Zhou Y. Temporal Trends and projections of bladder cancer burden in China from 1990 to 2030: findings from the global burden of disease study. Clin Epidemiol. 2022;14:1305–15.

Bjerregaard BK, Raaschou-Nielsen O, Sørensen M, Frederiksen K, Christensen J, Tjønneland A, Overvad K, Chapelon FC, Nagel G, Chang-Claude J, Bergmann MM, Boeing H, Trichopoulos D, Trichopoulou A, Oikonomou E, Berrino F, Palli D, Tumino R, Vineis P, Panico S, Peeters PH, Bueno-de-Mesquita HB, Kiemeney L, Gram IT, Braaten T, Lund E, Gonzalez CA, Berglund G, Allen N, Roddam A, Bingham S, Riboli E. Tobacco smoke and bladder cancer—in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2006;119:2412–6.

Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 2002;10:311–22.

Alkhateeb A, Atikukke G, Porter L, Fifield B-A, Cavallo-Medved D, Facca J, El-Gohary Y, Zhang T, Hamzeh O, Rueda L, Kanjeekal SM. Comprehensive targeted gene profiling to determine the genomic signature likely to drive progression of high-grade nonmuscle invasive bladder cancer to muscle invasive bladder cancer. J Clin Oncol. 2020;38:568–568.

Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, Hernández V, Linares Espinós E, Lorch A, Neuzillet Y, Rouanne M, Thalmann GN, Veskimäe E, Ribal MJ, van der Heijden AG. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79:82–104.

Song Q, Zhou R, Shu F, Fu W. Cuproptosis scoring system to predict the clinical outcome and immune response in bladder cancer. Front Immunol. 2022;13:958368.

Hu J, Yu A, Othmane B, Qiu D, Li H, Li C, Liu P, Ren W, Chen M, Gong G, Guo X, Zhang H, Chen J, Zu X. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. Theranostics. 2021;11:3089–108.

Chi M, Liu J, Mei C, Shi Y, Liu N, Jiang X, Liu C, Xue N, Hong H, Xie J, Sun X, Yin B, Meng X, Wang B. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer. J Exp Clin Cancer Res. 2022;41:175.

Yang R, Zhang W, Shang X, Chen H, Mu X, Zhang Y, Zheng Q, Wang X, Liu Y. Neutrophil-related genes predict prognosis and response to immune checkpoint inhibitors in bladder cancer. Front Pharmacol. 2022;13:1013672.

Zheng Z, Mao S, Zhang W, Liu J, Li C, Wang R, Yao X. Dysregulation of the immune microenvironment contributes to malignant progression and has prognostic value in bladder cancer. Front Oncol. 2020;10:542492.

Luo WJ, Tian X, Xu WH, Qu YY, Zhu WK, Wu J, Ma CG, Zhang HL, Ye DW, Zhu YP. Construction of an immune-related LncRNA signature with prognostic significance for bladder cancer. J Cell Mol Med. 2021;25:4326–39.

Jing W, Wang G, Cui Z, Xiong G, Jiang X, Li Y, Li W, Han B, Chen S, Shi B. FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell-mediated bladder cancer immune surveillance. Cancer Res. 2022;82:114–29.

Guillamón CF, Gimeno L, Server G, Martínez-Sánchez MV, Escudero JF, López-Cubillana P, Cabezas-Herrera J, Campillo JA, Abellan DJ, Martínez-García J, Martínez-Escribano J, Ferri B, López-Álvarez MR, Moreno-Alarcón C, Moya-Quiles MR, Muro M, Minguela A. Immunological risk stratification of bladder cancer based on peripheral blood natural killer cell biomarkers. Eur Urol Oncol. 2021;4:246–55.

Xu Y, Zeng H, Jin K, Liu Z, Zhu Y, Xu L, Wang Z, Chang Y, Xu J. Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. J Immunother Cancer. 2022;10:e003416.

Miyake M, Hori S, Morizawa Y, Tatsumi Y, Nakai Y, Anai S, Torimoto K, Aoki K, Tanaka N, Shimada K, Konishi N, Toritsuka M, Kishimoto T, Rosser CJ, Fujimoto K. CXCL1-mediated interaction of cancer cells with tumor-associated macrophages and cancer-associated fibroblasts promotes tumor progression in human bladder cancer. Neoplasia. 2016;18:636–46.

Groeneveld CS, Fontugne J, Cabel L, Bernard-Pierrot I, Radvanyi F, Allory Y, de Reyniès A. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. Eur J Cancer. 2021;148:181–9.

Lee HW, Chung W, Lee HO, Jeong DE, Jo A, Lim JE, Hong JH, Nam DH, Jeong BC, Park SH, Joo KM, Park WY. Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Med. 2020;12:47.

Ni Z, Sun P, Zheng J, Wu M, Yang C, Cheng M, Yin M, Cui C, Wang G, Yuan L, Gao Q, Li Y. JNK Signaling promotes bladder cancer immune escape by regulating METTL3-mediated m6A modification of PD-L1 mRNA. Cancer Res. 2022;82:1789–802.

Zhang D, Reyes RM, Osta E, Kari S, Gupta HB, Padron AS, Kornepati AVR, Kancharla A, Sun X, Deng Y, Wu B, Vadlamudi R, Li R, Svatek RS, Curiel TJ. Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy. Cancer Med. 2021;10:2137–52.

Liu Z, Tang Q, Qi T, Othmane B, Yang Z, Chen J, Hu J, Zu X. A robust hypoxia risk score predicts the clinical outcomes and tumor microenvironment immune characters in bladder cancer. Front Immunol. 2021;12:725223.

McNiel EA, Tsichlis PN. Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1. Signal Transduct Target Ther. 2017;2:16045.

Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L. Intratumoral CD4(+) T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell. 2020;181:1612-1625.e1613.

Zhou M, Zhang Z, Bao S, Hou P, Yan C, Su J, Sun J. Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer. Brief Bioinform. 2021;22:bbaa047.

Liu Q, You B, Meng J, Huang CP, Dong G, Wang R, Chou F, Gao S, Chang C, Yeh S, Xu W. Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling. Cancer Gene Ther. 2022;29:1988–2000.

Massari F, Ciccarese C, Santoni M, Iacovelli R, Mazzucchelli R, Piva F, Scarpelli M, Berardi R, Tortora G, Lopez-Beltran A, Cheng L, Montironi R. Metabolic phenotype of bladder cancer. Cancer Treat Rev. 2016;45:46–57.

Cao D, Qi Z, Pang Y, Li H, Xie H, Wu J, Huang Y, Zhu Y, Shen Y, Zhu Y, Dai B, Hu X, Ye D, Wang Z. Retinoic acid-related orphan receptor C regulates proliferation, glycolysis, and chemoresistance via the PD-L1/ITGB6/STAT3 signaling axis in bladder cancer. Cancer Res. 2019;79:2604–18.

Pellerin È, Chabaud S, Pouliot F, Pelletier M, Bolduc S. Bisphenol A alters the energy metabolism of stromal cells and could promote bladder cancer progression. Cancers. 2021;13:5461.

Wigner P, Grębowski R, Bijak M, Saluk-Bijak J, Szemraj J. The interplay between oxidative stress, inflammation and angiogenesis in bladder cancer development. Int J Mol Sci. 2021;22:4483.

Islam MO, Bacchetti T, Ferretti G. Alterations of antioxidant enzymes and biomarkers of nitro-oxidative stress in tissues of bladder cancer. Oxid Med Cell Longev. 2019;2019:2730896.

Xie R, Cheng L, Huang M, Huang L, Chen Z, Zhang Q, Li H, Lu J, Wang H, Zhou Q, Huang J, Chen X, Lin T. NAT10 Drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer. Cancer Res. 2023;83:1666–83.

Wu J, Tan Z, Li H, Lin M, Jiang Y, Liang L, Ma Q, Gou J, Ning L, Li X, Guan F. Melatonin reduces proliferation and promotes apoptosis of bladder cancer cells by suppressing o-GlcNAcylation of cyclin-dependent-like kinase 5. J Pineal Res. 2021;71:e12765.

Chen Y, Wang HH, Chang HH, Huang YH, Wang JR, Changchien CY, Wu ST. Guggulsterone induces apoptosis and inhibits lysosomal-dependent migration in human bladder cancer cells. Phytomedicine. 2021;87:153587.

Shan G, Zhou X, Gu J, Zhou D, Cheng W, Wu H, Wang Y, Tang T, Wang X. Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by downregulating the Wnt/β-catenin pathway and upregulating PTEN. Cell Oncol. 2021;44:45–59.

Xu H, Ju L, Xiong Y, Yu M, Zhou F, Qian K, Wang G, Xiao Y, Wang X. E3 ubiquitin ligase RNF126 affects bladder cancer progression through regulation of PTEN stability. Cell Death Dis. 2021;12:239.

Wang X, He H, Rui W, Zhang N, Zhu Y, Xie X. TRIM38 triggers the uniquitination and degradation of glucose transporter type 1 (GLUT1) to restrict tumor progression in bladder cancer. J Transl Med. 2021;19:508.

Hoskin PJ, Sibtain A, Daley FM, Wilson GD. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer. 2003;89:1290–7.

Xu C, Yang X, Wang Y, Ding N, Han R, Sun Y, Wang Y. An analysis of the polymorphisms of the GLUT1 gene in urothelial cell carcinomas of the bladder and its correlation with p53, Ki67 and GLUT1 expressions. Cancer Gene Ther. 2017;24:297–303.

Li M, Che N, Jin Y, Li J, Yang W. CDKN3 Overcomes bladder cancer cisplatin resistance via LDHA-dependent glycolysis reprogramming. Onco Targets Ther. 2022;15:299–311.

Li T, Tong H, Yin H, Luo Y, Zhu J, Qin Z, Yin S, He W. Starvation induced autophagy promotes the progression of bladder cancer by LDHA mediated metabolic reprogramming. Cancer Cell Int. 2021;21:597.

Liao AC, Li CF, Shen KH, Chien LH, Huang HY, Wu TF. Loss of lactate dehydrogenase B subunit expression is correlated with tumour progression and independently predicts inferior disease-specific survival in urinary bladder urothelial carcinoma. Pathology. 2011;43:707–12.

Qiu H, Hu X, He C, Yu B, Li Y, Li J. Identification and validation of an individualized prognostic signature of bladder cancer based on seven immune related genes. Front Genet. 2020;11:12.

Zhang J, Huang C, Yang R, Wang X, Fang B, Mi J, Yuan H, Mo Z, Sun Y. Identification of immune-related subtypes and construction of a novel prognostic model for bladder urothelial cancer. Biomolecules. 2022;12:1670.

Cao R, Yuan L, Ma B, Wang G, Tian Y. Immune-related long non-coding RNA signature identified prognosis and immunotherapeutic efficiency in bladder cancer (BLCA). Cancer Cell Int. 2020;20:276.

Gao Z, Chen C, Gu P, Chen J, Liu X, Shen J. The tumor microenvironment and prognostic role of autophagy- and immune-related genes in bladder cancer. Cancer Biomark. 2022;35:293–303.

Ding K, Zheng Z, Han Y, Huang X. Prognostic values of the immune microenvironment-related non-coding RNA IGF2BP2-AS1 in bladder cancer. Cell Cycle. 2022;21:2533–49.

Rogers RF, Walton MI, Cherry DL, Collins I, Clarke PA, Garrett MD, Workman P. CHK1 inhibition is synthetically lethal with loss of B-family DNA polymerase function in human lung and colorectal cancer cells. Cancer Res. 2020;80:1735–47.

Zhang C, Shen Y, Gao L, Wang X, Huang D, Xie X, Xu D, He H. Targeting POLE2 creates a novel vulnerability in renal cell carcinoma via modulating stanniocalcin 1. Front Cell Dev Biol. 2021;9:622344.

Spier I, Holzapfel S, Altmüller J, Zhao B, Horpaopan S, Vogt S, Chen S, Morak M, Raeder S, Kayser K, Stienen D, Adam R, Nürnberg P, Plotz G, Holinski-Feder E, Lifton RP, Thiele H, Hoffmann P, Steinke V, Aretz S. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. Int J Cancer. 2015;137:320–31.

Ni L, Sun P, Fan X, Li Z, Ren H, Li J. Berberine inhibits FOXM1 dependent transcriptional regulation of POLE2 and interferes with the survival of lung adenocarcinoma. Front Pharmacol. 2021;12:775514.

Li J, Wang J, Yu J, Zhao Y, Dong Y, Fan Y, Li N, Zhang Y, Wang Y. Knockdown of POLE2 expression suppresses lung adenocarcinoma cell malignant phenotypes in vitro. Oncol Rep. 2018;40:2477–86.

Zhu Y, Chen G, Song Y, Chen Z, Chen X. POLE2 knockdown reduce tumorigenesis in esophageal squamous cells. Cancer Cell Int. 2020;20:388.

Lee H, Kim K, Woo J, Park J, Kim H, Lee KE, Kim H, Kim Y, Moon KC, Kim JY, Park IA, Shim BB, Moon JH, Han D, Ryu HS. Quantitative proteomic analysis identifies AHNAK (Neuroblast Differentiation-Associated Protein AHNAK) as a novel candidate biomarker for bladder urothelial carcinoma diagnosis by liquid-based cytology. Mol Cell Proteomics. 2018;17:1788–802.

Zhang Z, Yu Y, Li P, Wang M, Jiao W, Liang Y, Niu H. Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer. Front Immunol. 2022;13:954616.

Benaud C, Gentil BJ, Assard N, Court M, Garin J, Delphin C, Baudier J. AHNAK interaction with the annexin 2/S100A10 complex regulates cell membrane cytoarchitecture. J Cell Biol. 2004;164:133–44.

Zheng M, Liu J, Bian T, Liu L, Sun H, Zhou H, Zhao C, Yang Z, Shi J, Liu Y. Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma. Int Immunopharmacol. 2021;90:107134.

Chen B, Wang J, Dai D, Zhou Q, Guo X, Tian Z, Huang X, Yang L, Tang H, Xie X. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer. J Exp Clin Cancer Res. 2017;36:65.

Kouno M, Kondoh G, Horie K, Komazawa N, Ishii N, Takahashi Y, Takeda J, Hashimoto T. Ahnak/Desmoyokin is dispensable for proliferation, differentiation, and maintenance of integrity in mouse epidermis. J Invest Dermatol. 2004;123:700–7.

Shankar J, Messenberg A, Chan J, Underhill TM, Foster LJ, Nabi IR. Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells. Cancer Res. 2010;70:3780–90.

Zhang P, Yang Q. Overexpression of SHMT2 predicts a poor prognosis and promotes tumor cell growth in bladder cancer. Front Genet. 2021;12:682856.

Zhong W, Wang D, Yao B, Chen X, Wang Z, Qu H, Ma B, Ye L, Qiu J. Integrative analysis of prognostic long non-coding RNAs with copy number variation in bladder cancer. J Zhejiang Univ Sci B. 2021;22:664–81.

Khalil BD, Sanchez R, Rahman T, Rodriguez-Tirado C, Moritsch S, Martinez AR, Miles B, Farias E, Mezei M, Nobre AR, Singh D, Kale N, Sproll KC, Sosa MS, Aguirre-Ghiso JA. An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy. J Exp Med. 2022;219:e2021083.

Gui CP, Li JY, Fu LM, Luo CG, Zhang C, Tang YM, Zhang LZ, Shu GN, Wu RP, Luo JH. Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer. J Big Data. 2022;9:88.

Sun J, Yue W, You J, Wei X, Huang Y, Ling Z, Hou J. Identification of a novel ferroptosis-related gene prognostic signature in bladder cancer. Front Oncol. 2021;11:730716.

Su H, Tao T, Yang Z, Kang X, Zhang X, Kang D, Wu S, Li C. Circular RNA cTFRC acts as the sponge of MicroRNA-107 to promote bladder carcinoma progression. Mol Cancer. 2019;18:27.

Huang X, Liang H, Zhang H, Tian L, Cong P, Wu T, Zhang Q, Gao X, Li W, Chen A, Zhang Y, Dong Q, Wan H, He M, Dai D, Li Z, Xiong L. The potential mechanism of cancer patients appearing more vulnerable to SARS-CoV-2 and poor outcomes: a pan-cancer bioinformatics analysis. Front Immunol. 2021;12:804387.

Gao L, Ren R, Shen J, Hou J, Ning J, Feng Y, Wang M, Wu L, Sun Y, Wang H, Wang D, Cao J. Values of OAS gene family in the expression signature, immune cell infiltration and prognosis of human bladder cancer. BMC Cancer. 2022;22:1016.

Xu C, Pei D, Liu Y, Yu Y, Guo J, Liu N, Kang Z. Identification of a novel tumor microenvironment prognostic signature for bladder urothelial carcinoma. Front Oncol. 2022;12:818860.

Liu C, Liu D, Wang F, Liu Y, Xie J, Xie J, Xie Y. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma. Front Immunol. 2022;13:1038927.

Chen X, Qiu H, Wang C, Yuan Y, Tickner J, Xu J, Zou J. Molecular structure and differential function of choline kinases CHKα and CHKβ in musculoskeletal system and cancer. Cytokine Growth Factor Rev. 2017;33:65–72.

Yang L, Huang W, Bai X, Wang H, Wang X, Xiao H, Li Y. Androgen dihydrotestosterone promotes bladder cancer cell proliferation and invasion via EPPK1-mediated MAPK/JUP signalling. Cell Death Dis. 2023;14:363.

Helzlsouer KJ, Comstock GW, Morris JS. Selenium, lycopene, alpha-tocopherol, beta-carotene, retinol, and subsequent bladder cancer. Cancer Res. 1989;49:6144–8.

Toki K, Enokida H, Kawakami K, Chiyomaru T, Tatarano S, Yoshino H, Uchida Y, Kawahara K, Nishiyama K, Seki N, Nakagawa M. CpG hypermethylation of cellular retinol-binding protein 1 contributes to cell proliferation and migration in bladder cancer. Int J Oncol. 2010;37:1379–88.

Yang M, Liu X, Tang X, Sun W, Ji Z. LC-MS based urine untargeted metabolomic analyses to identify and subdivide urothelial cancer. Front Oncol. 2023;13:1160965.

Niu L, Ding L, Lu C, Zuo F, Yao K, Xu S, Li W, Yang D, Xu X. Flavokawain A inhibits cytochrome P450 in in vitro metabolic and inhibitory investigations. J Ethnopharmacol. 2016;191:350–9.

Kuwada H, Ihara K, Imaishi H. Development of a new assay system for bladder cancer using interactions between cytochromes P450 and serum. Drug Metab Pharmacokinet. 2022;47:100472.

Zhang Y, Chen Q, Gong M, Zeng Y, Gao D. Gene regulatory networks analysis of muscle-invasive bladder cancer subtypes using differential graphical model. BMC Genomics. 2021;22:863.

Kong DB, Chen F, Sima N. Focal adhesion kinases crucially regulate TGFβ-induced migration and invasion of bladder cancer cells via Src kinase and E-cadherin. Onco Targets Ther. 2017;10:1783–92.

Kong D, Chen F, Sima NI. Inhibition of focal adhesion kinase induces apoptosis in bladder cancer cells via Src and the phosphatidylinositol 3-kinase/Akt pathway. Exp Ther Med. 2015;10:1725–31.

Zhao F, Yang T, Zhou L, Li R, Liu J, Zhao J, Jia R. Sig1R activates extracellular matrix-induced bladder cancer cell proliferation and angiogenesis by combing β-integrin. Aging. 2023;15:4182–201.